Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Ibrutinib
Related studies linked through entity extraction aliases.
A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation
- Status
- COMPLETED
- Phase
- PHASE3
Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)
- Status
- WITHDRAWN
- Phase
- PHASE2
Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients
- Status
- TERMINATED
- Phase
- PHASE2
Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
- Status
- COMPLETED
- Phase
- PHASE2
Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
Study to Assess the Bioequivalence of Ibrutinib 140 Milligram (mg) Tablet to 140 mg IMBRUVICA Capsule
- Status
- COMPLETED
- Phase
- PHASE1
TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
- Status
- COMPLETED
- Phase
- PHASE2
Ibrutinib in Previously Untreated Binet Stage a Chronic Lymphocytic Leukemia with Risk of Disease Progression
- Status
- COMPLETED
- Phase
- PHASE3
Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- N/A
Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone
- Status
- WITHDRAWN
- Phase
- PHASE1